Tag: Sutent

jan naritomi hart

10 Highlights of the Year 2011 for the Carcinoid and Neuroendocrine Tumor Community

December 15, 2011

As the Carcinoid Cancer Foundation looks back on the year 2011, there were many significant events and advances for the carcinoid and neuroendocrine tumor (NET) community.  Here are 10 of the year’s important stories:

1)     The FDA approved the first…

READ MORE
Richard R.P. Warner, MD2

Pancreatic Neuroendocrine Tumors: A Rare Cancer

August 26, 2011

From your next door neighbor to Steve Jobs, co-founder of Apple who just announced that he is stepping down as CEO of the company, pancreatic neuroendocrine tumors (pNETs) affect less than 1 person in 100,000 in the United States.  This rare cancer is often…

READ MORE
pfizer logo1

Breaking News: FDA Approves Pfizer’s Sutent for Pancreatic NET Cancer Patients

May 20, 2011

The US Food and Drug Administration today announced approval of Pfizer’s Sutent (sunitinib) for advanced pancreatic neuroendocrine tumor cancer patients with tumors that cannot be removed by surgery or that have spread  (metastasized) to …

READ MORE
Pfizer logo

Breaking News: FDA Approves Pfizer’s Sutent for Pancreatic NET Cancer Patients

May 20, 2011

The US Food and Drug Administration today announced approval of Pfizer’s Sutent (sunitinib) for advanced pancreatic neuroendocrine tumor cancer patients with tumors that cannot be removed by surgery or that have spread  (metastasized) to …

READ MORE
FDA logo

Carcinoid Cancer Foundation to Speak on Behalf of NET Cancer Patients at April 12, 2011 FDA Oncologic Drugs Advisory Committee Meeting

March 24, 2011

Grace Goldstein, Chief Operating Officer of the Carcinoid Cancer Foundation, will speak at the Open Public Hearing segment during the U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee Meeting on April 12, 2011 in Silver …

READ MORE